A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia

NCT02016755 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Critical Limb Ischemia
Vascular Diseases
Peripheral Arterial Disease

Interventions

BIOLOGICAL: HGF Plasmid

Sponsor

AnGes USA, Inc.